A phase II study of nab-paclitaxel and gemcitabine as first line therapy in patients with cholangiocarcinoma ineligible for cisplatin-based chemotherapy (NACHO)
Conclusions: The NACHO trial supports safety and efficacy of nab-paclitaxe l and gemcitabine in patients with advanced CCA ineligible for cisplatin-based therapy and should be further evaluated in a larger prospective trial.
Clinical trial information: EudraCT-No.: 2014-004981-52 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - January 9, 2023 Category: Cancer & Oncology Source Type: research
Expertenreport Immunthrombozytopenie - Aktuelle Diagnostik und Therapie
not abstract, please contact Dr. Hentzelt, Publication manager Karger (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 26, 2022 Category: Cancer & Oncology Source Type: research
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2022
Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 16, 2022 Category: Cancer & Oncology Source Type: research
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2022
(Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 16, 2022 Category: Cancer & Oncology Source Type: research
Thoracic Oncology Highlights from the
European Society for Medical Oncology Annual Meeting 2022
We report on highlights in the field of thoracic oncology. The topics cover oncogene-driven and immunotherapy-based therapeutic concepts in metastatic and non-metastatic NSCLC. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 16, 2022 Category: Cancer & Oncology Source Type: research
Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrospective Cohort Study
Discussion: A structured follow-up after pancreatic ductal adenocarcinoma resection may have an impact on patient outcome. Prospective trials are needed to evaluate the clinical impact of post-operative follow-up programmes.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 16, 2022 Category: Cancer & Oncology Source Type: research
Clinical impact of structured post-operative surveillance in resected pancreatic adenocarcinoma: Results from a retrospective cohort study
Conclusion
A structured follow-up after PDAC resection may have an impact on patient outcome. Prospective trials are needed to evaluate the clinical impact of post-operative follow-up programs. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 16, 2022 Category: Cancer & Oncology Source Type: research
Stereotactic Radiotherapy in Early-Stage Breast Cancer in Neoadjuvant and Exclusive Settings: A Systematic Review
Conclusions: Relative low toxicity rates, the reduced treatment volumes in the neoadjuvant setting, and the possibility to replace surgery when not feasible in exclusive setting resulted to be main advantages for SBRT in BC. Current evidence shows that both the neoadjuvant and the definitive settings seem to be promising clinical scenarios for SBRT, especially for EBC.Oncol Res Treat (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 12, 2022 Category: Cancer & Oncology Source Type: research
Stereotactic Radiotherapy in Early-Stage Breast Cancer in Neoadjuvant and Exclusive Settings: A Systematic Review
Conclusions: Relative low toxicity rates, the reduced treatment volumes in the neoadjuvant setting, and the possibility to replace surgery when not feasible in exclusive setting resulted to be main advantages for SBRT in BC. Current evidence shows that both the neoadjuvant and the definitive settings seem to be promising clinical scenarios for SBRT, especially for EBC. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 12, 2022 Category: Cancer & Oncology Source Type: research
Stereotactic radiotherapy in early stage breast cancer in neoadjuvant and exclusive settings: a systematic review
Conclusions
Relative low toxicity rates; the reduced treatment volumes in the neoad juvant setting and the possibility to replace surgery when not feasible in exclusive setting, resulted to be main advantages for SBRT in BC. Current evidence showed as both the neoadjuvant and the definitive settings seem to be promising clinical scenarios for SBRT especially for EBC. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 12, 2022 Category: Cancer & Oncology Source Type: research
Pan-HER tyrosine kinase inhibitor pyrotinib enhances radiosensitivity via ERK1/2 pathway in HER2-positive gastric cancer
Conclusions: Our results demonstrated that pyroti nib can induce radiosensitivity in HER2-positive gastric cancer in vivo and in vitro. This effect is through reducing irradiation-induced HER2 entry into the nucleus and inhibiting ERK1/2 signaling pathway. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 8, 2022 Category: Cancer & Oncology Source Type: research
Genomic Landscape of Circulating-Tumor DNA in a Diverse Cohort of Metastatic Breast Cancer Patients
Conclusion
Liquid biopsies are effective tools that can reveal clinically relevant information including mutational status and therapeutic options. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - December 8, 2022 Category: Cancer & Oncology Source Type: research
